Life Biosciences Closes $80M Series D Financing

Life Biosciences, a clinical-stage biotechnology company focused on cellular rejuvenation therapies, has closed a fully-subscribed $80 million Series D financing. The company will use proceeds to support operations into the second half of 2027.

Funding will include completion of its recently initiated Phase 1 clinical trial of ER-100 in optic neuropathies and continued advancement of its Partial Epigenetic Reprogramming (PER) platform across multiple therapeutic indications. ER-100’s Phase 1 trial is designed to assess safety and tolerability in patients with open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION).